| Title |
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, January 2013
|
| DOI | 10.1007/s00280-013-2079-z |
| Pubmed ID | |
| Authors |
Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin M. Posadas, Evan Y. Yu, Michael R. Harrison, Justine Y. Bruce, Steve Y. Cho, Gregory E. Wilding, Gerald J. Fetterly, David G. Hangauer, Min-Fun R. Kwan, Lyn M. Dyster, Michael A. Carducci |
| Abstract |
KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymerization. In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer. We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naïve bone-metastatic castration-resistant prostate cancer (CRPC). |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Netherlands | 1 | 2% |
| Italy | 1 | 2% |
| Unknown | 58 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 21% |
| Researcher | 9 | 15% |
| Student > Bachelor | 8 | 13% |
| Student > Master | 7 | 11% |
| Other | 5 | 8% |
| Other | 6 | 10% |
| Unknown | 13 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 31% |
| Agricultural and Biological Sciences | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Nursing and Health Professions | 4 | 7% |
| Other | 8 | 13% |
| Unknown | 16 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2019.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#87,553
of 288,375 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#15
of 31 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,375 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.